APA način citiranja

Stabile, L., Egloff, A., Gibson, M., Gooding, W., Ohr, J., Zhou, P., . . . Bauman, J. (2017). IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncol.

Čikaški stil citiranja

Stabile, L.P., et al. "IL6 Is Associated With Response to Dasatinib and Cetuximab: Phase II Clinical Trial With Mechanistic Correlatives in Cetuximab-resistant Head and Neck Cancer." Oral Oncol 2017.

MLA način citiranja

Stabile, L.P., et al. "IL6 Is Associated With Response to Dasatinib and Cetuximab: Phase II Clinical Trial With Mechanistic Correlatives in Cetuximab-resistant Head and Neck Cancer." Oral Oncol 2017.